Linked Life Data

15451219

Source:http://linkedlifedata.com/resource/pubmed/id/15451219

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9440
pubmed:dateCreated
2004-9-28
pubmed:abstractText
Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST). We aimed to assess dose dependency of response and progression-free survival with imatinib for metastatic GIST.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1474-547X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
364
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1127-34
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:articleTitle
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
pubmed:affiliation
Department of Medical Oncology, Erasmus University Medical Centre, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands. j.verweij@erasmusmc.nl
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Meta-Analysis, Clinical Trial, Phase III